ФЕНОМЕН НЕВОCСТАНОВЛЕННОГО КОРОНАРНОГО КРОВОТОКА (NO-REFLOW) В ПРАКТИКЕ ЭНДОВАСКУЛЯРНОГО ХИРУРГА

Феномен невосстановленного коронарного кровотока, или феномен no-reflow, представляет собой осложнение чрескожного коронарного вмешательства и проявляется в виде отсутствия заполнения дистального коронарного русла. Основной причиной этого феномена служит дистальная эмболия коронарных артерий атероматозными и тромботическими массами. В статье приводятся различные классификации оценки реперфузии миокарда и коронарного кровотока. Также затрагивается вопрос использования аспирационных катетеров, ингибиторов гликопротеинов IIb/IIIa рецепторов и других препаратов, влияющих на прогноз больных с этим феноменом.

1. Resnic F.S., Wainstein M., Lee M.K.Y. et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am. Heart J. 2003; 145: 42–6.

2. Gerber B.L., Rochitte C.E., Melin J.A. et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation. 2000; 101: 2734–41.

3. Rezkella S.H., Kloner R.A. No-reflow phenomenon. Circulation. 2002; 105: 656–62.

4. Piana R.N., Paik G.Y., Moscucci M. et al. Incidence and treatment of “no-reflow” after percutaneous coronary intervention. Circulation. 1994; 89: 2514–8.

5. Majno G., Ames A. III, Chiang J. et al. No-reflow after cerebral ischemia. Lancet. 1967; 2: 569–70.

6. Kloner R.A., Ganote C.E., Jennings R.B. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 1974; 54: 1496–508.

7. Topol E.J., Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000; 101: 570–80.

8. Van’t Hof A.W., Liem A., Suryapranata H. et al. Angiographic assessment of myocardial perfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation. 1998; 97: 2302–6.

9. Cannon C.P., Sharis P.J., Schweiger M.J. et al. Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis in Myocardial Infarction. Am. J. Cardiol. 1997; 80: 696–9.

10. Gibson C.M., Murphy S.A., Rizzo M.J. et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 1999; 99: 1945–50.

11. Stone G.W., Peterson M.A., Lansky A.J. et al. Impact of normalized myocar-dial perfusion after successful angioplasty in acute myocardial infarction. J. Am. Coll. Cardiol. 2002; 39: 591–7.

12. De Luca G., van’t Hof A.W., Otter-vanger J.P. et al. Unsuccessful reper-fusion in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. Am. Heart J. 2005; 150: 557–62.

13. Montalescot G., Barragan P., Witten-berg O. et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 2001; 344: 1895–903.

14. Petronio A.S., Rovai D., Musumeci G. et al. Effects of abciximab on micro-vascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur. Heart J. 2003; 24: 67–76.

15. De Luca G., Suryapranata H., Stone G.W. et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J. Am. Med. Assoc. 2005; 293: 1759–65.

16. De Luca L., Sardella G., Davidson C.J. et al. Impact of intracoronary aspiration thrombectomy uring primary angioplasty on left ventricular remodeling in patients with anterior ST-elevation myocardial infarction. Heart. 2006; 92: 951–7.

17. Ole Fröbert, Bo Lagerqvist, Göran K. Olivecrona et al. Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. N. Engl. J. Med. 2013. DOI: 10.1056/NEJMoa1308789

18. Vlaar P.J., Svilaas T., van der Horst I.C. et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008; 371, 9628: 1915–20.

19. Mahaffey K.W., Puma J.A., Barbagaleta N.A. et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Car-diol. 1999; 34: 1711–20.

20. Ross A.M., Gibbons R.J., Stone G.W. et al. A randomized double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol. 2005; 45: 1775–80.

21. Ishii H., Ichimiya S., Kanashiro et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment elevation myocardial infarction. Circulation. 2005; 112: 1284–8.